Tasmanian devils, those quirky marsupial scavengers, are facing a dire threat: a contagious cancer that has decimated their population. But amidst this grim scenario, a beacon of hope emerges through a groundbreaking research partnership. The Colossal Foundation and the University of Tasmania have joined forces to tackle the devil facial tumour disease (DFTD), a formidable challenge that has already claimed the lives of approximately 80% of wild devils since its discovery in 1996. This disease, a cunning duo of cancers (DFT1 and DFT2), spreads through bites during feeding and mating, leading to fatal tumours around the mouth and face. The partnership is pursuing a two-pronged strategy, combining vaccine development and gene editing.
A Vaccine Approach
One of the key players in this endeavor is Andrew Flies and his team at the Menzies Institute for Medical Research. They've crafted an oral bait vaccine, a clever design that aims to train the devil's immune system to combat both cancers. The Colossal Foundation's involvement is pivotal, as they've established a colony of fat-tailed dunnarts, a mouse-sized marsupial relative of the devil, in Hobart. This colony serves as a crucial testing ground for the vaccine's safety before any trials on devils commence. Flies acknowledges the challenges of working with an endangered species and the scarcity of marsupial research tools, but the partnership with the Colossal Foundation offers a ray of light. By combining their expertise, they hope to accelerate vaccine development and explore gene-editing strategies to bolster the vaccine's effectiveness.
Gene Editing: Targeting the LZTR1 Gene
The other prong of the partnership's strategy focuses on a gene called LZTR1, which researchers believe plays a pivotal role in the origin of the tumours. The ambitious goal is to test whether editing this gene could reduce the susceptibility of devils to the cancers. This approach, if successful, could be a game-changer in the fight against DFTD.
Broader Implications and Future Directions
The decline of Tasmanian devils has far-reaching consequences for the ecosystem. As apex scavengers, their disappearance disrupts the balance of the food chain, allowing feral cats to spread unchecked. The partnership's efforts not only focus on saving the devils but also on understanding the broader ecological impact. The Colossal Foundation's previous work in attempting to bring back the thylacine has equipped them with valuable marsupial expertise, which they are now applying to living species.
Conclusion: A Ray of Hope in the Fight Against Cancer
While the vaccine still needs to pass safety trials before it can be tested on wild devils, this partnership represents a significant step forward in the battle against devil facial tumour disease. The combination of vaccine development and gene editing offers a promising future for the Tasmanian devil population, and the broader ecosystem that depends on their presence. As we eagerly await the outcomes of these scientific endeavors, one thing is clear: the resilience of nature and the power of human innovation can indeed make a difference, even in the face of such formidable challenges.
